IRIS
PIERMATTEO, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.898
AS - Asia 2.396
EU - Europa 1.705
SA - Sud America 440
OC - Oceania 82
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.788
SG - Singapore 1.173
IT - Italia 650
CN - Cina 419
BR - Brasile 349
RU - Federazione Russa 303
VN - Vietnam 218
HK - Hong Kong 202
DE - Germania 148
GB - Regno Unito 104
JP - Giappone 101
IE - Irlanda 91
BD - Bangladesh 86
FI - Finlandia 83
AU - Australia 75
CA - Canada 61
IN - India 61
ES - Italia 59
FR - Francia 53
NL - Olanda 46
AR - Argentina 39
PL - Polonia 35
SE - Svezia 31
AT - Austria 30
MX - Messico 29
TR - Turchia 25
ID - Indonesia 21
CO - Colombia 16
IQ - Iraq 16
CZ - Repubblica Ceca 15
ZA - Sudafrica 15
VE - Venezuela 11
EG - Egitto 10
UA - Ucraina 10
EC - Ecuador 9
CH - Svizzera 8
LT - Lituania 8
PH - Filippine 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
NZ - Nuova Zelanda 7
BE - Belgio 6
KR - Corea 6
MY - Malesia 6
NG - Nigeria 6
DZ - Algeria 5
HN - Honduras 5
IR - Iran 5
JO - Giordania 5
PK - Pakistan 5
UZ - Uzbekistan 5
CR - Costa Rica 4
IL - Israele 4
MA - Marocco 4
PE - Perù 4
TN - Tunisia 4
CM - Camerun 3
JM - Giamaica 3
KE - Kenya 3
KH - Cambogia 3
KZ - Kazakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
CL - Cile 2
DK - Danimarca 2
GR - Grecia 2
HU - Ungheria 2
LV - Lettonia 2
OM - Oman 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
IS - Islanda 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
MU - Mauritius 1
NI - Nicaragua 1
NP - Nepal 1
PR - Porto Rico 1
SI - Slovenia 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 8.578
Salva come PNG Salva come JPEG
Città #
Singapore 705
Wilmington 474
San Jose 407
Houston 307
Ashburn 236
Rome 214
Hong Kong 199
Chandler 195
Beijing 161
New York 153
Fairfield 137
Los Angeles 111
Santa Clara 108
Council Bluffs 104
Tokyo 100
Ho Chi Minh City 77
The Dalles 74
Dublin 70
Helsinki 65
Milan 60
Woodbridge 54
Hanoi 53
Munich 53
Dallas 51
Buffalo 50
Seattle 44
Nuremberg 42
Cambridge 38
Moscow 37
Ann Arbor 35
Orem 34
São Paulo 32
Medford 31
Chicago 29
La Veta 29
Melbourne 28
Sydney 28
London 27
Montreal 26
Engelhard 25
Naples 24
Chennai 21
Warsaw 19
Lauterbourg 18
Frankfurt am Main 17
Poplar 17
Redondo Beach 17
Stockholm 17
Washington 17
Brooklyn 16
Canberra 16
Genoa 15
Lappeenranta 15
Lawrence 15
Mexico City 15
North Bergen 15
Toronto 15
Vienna 15
Amsterdam 14
Denver 14
Jakarta 14
Madrid 14
Barcelona 13
Cedarhurst 13
San Francisco 13
St. George 13
Manchester 12
Phoenix 12
Bari 11
Creede 11
Johannesburg 11
San Diego 11
Haiphong 9
Palermo 9
Paris 9
Atlanta 8
Boston 8
Brasília 8
Brno 8
Charlotte 8
Guangzhou 8
Mumbai 8
Padova 8
Palo Alto 8
Rio de Janeiro 8
Auckland 7
Belo Horizonte 7
Florence 7
Hải Dương 7
Pesaro 7
Suzhou 7
Ankara 6
Biên Hòa 6
Boardman 6
Chandigarh 6
Da Nang 6
Dearborn 6
Erbil 6
Fortaleza 6
Genzano di Roma 6
Totale 5.386
Salva come PNG Salva come JPEG
Nome #
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 381
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 333
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 265
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 253
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 210
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 188
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 180
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 175
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 162
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 162
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 158
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 155
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 152
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 145
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 137
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 130
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 126
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 124
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 120
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 117
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 106
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 106
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 101
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 100
Human monocyte-derived macrophages (MDM): model 1 (GM-CSF) 96
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 94
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 94
The acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer in vivo, impairs HBsAg secretion and affects its structural stability in vitro 93
HUMAN ENDOGENOUS RETROVIRUSES EXPRESSION CORRELATES WITH HIV RESERVOIR, LYMPHOCYTES ACTIVATION AND LOW CD4 COUNT IN VIROLOGICALLY SUPPRESSED PATIENTS 92
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 92
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 90
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 90
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses 89
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 88
ULTRASENSITIVE HBV-RNA QUANTIFICATION AS A PROMISING BIOMARKER TO OPTIMIZE THE STAGING OF CHRONIC HBV INFECTION AND TO DETECT MINIMAL VIRAL ACTIVITY UNDER PROLONGED VIROLOGICAL SUPPRESSION AND OCCULT HBV INFECTION. 88
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 88
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 88
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 87
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 87
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 86
Impact of pre-existent drug resistance on virological efficacy of single tablet regimens in people living with HIV 85
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 82
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression. 81
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 81
POTENT ANTIVIRAL ACTIVITY OF NEW GENERATION HIV-1 MATURATION INHIBITORS ON HUMAN PRIMARY CELLS 80
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 78
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 77
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 76
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 75
PREVALENCE AND OUTCOME OF HEPATITIS DELTA VIRUS (HDV) INFECTION AMONG PERSONS LIVING WITH HIV (PLWH) IN ITALY: THE DELTA-ICONA STUDY OC 150 75
Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization 74
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage 74
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 74
Kinetics of hepatitis B virus replication in anti-HBc positive/HBsAg-negative people with HIV switching to tenofovir sparing therapy 72
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles 72
Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients 71
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 70
Heterogeneity in the diagnostic sensitivities of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study. 69
HDV INFECTION IS STABLE IN CENTRAL ITALY ACROSS THE LAST TWO DECADES AND IS CHARACTERIZED BY THE CIRCULATION OF MULTIPLE HDV SUB-GENOTYPES 1 WITH A DIFFERENT PRO-INFLAMMATORY POTENTIAL 69
Evidence of abundant transcriptionally active HBV-integration events involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection. 68
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 68
THE ENRICHMENT OF POSITIVELY CHARGED AMINO ACIDS IN HBsAg C-TERMINUS IMPAIRS HBsAg SECRETION, AFFECTS ITS STRUCTURAL STABILITY AND IS CORRELATED WITH HBV-INDUCED LIVER CANCER. 67
KINETICS OF THE THREE HBSAG ISOFORMS ALONG WITH HDV-RNA PREDICT VIROLOGICAL RESPONSE IN CHD PATIENTS TREATED WITH BULEVIRTIDE UP TO 96 WEEKS P 215 66
Kinetics of the Three HBsAg Isoforms along with HDV-RNA Predict Virological Response in CHD Patients Treated with Bulevirtide for 48 Weeks 66
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 66
Total HIV DNA and cell-associated HIV RNA viral reservoirs in PBMCs and GALT in patients on triple-ART and switching to dual-ART regimens. 64
Heterogeneity in the diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study. 64
Cryptic HBV activity is frequently observed among anti-HBc positive/HBsAg negative people living with HIV infection during HBV-active art and can jeopardize the full control of HIV replication. 64
New insights into hepatitis B virus lymphotropism: implications for HBV-related lymphomagenesis 61
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 59
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 59
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection 59
Different diagnostic performances of HDV RNA quantification assays used in clinical practicein Italy: results from a national quality control multicenter study. 56
Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleos(t)ide analogue systematic discontinuation in non cirrhotic patients with chronic hepatitis B 55
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 55
The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH 53
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 53
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 52
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 52
Total HIV-DNA quantification (automated Elitech InGenius platform) in antiretroviral treated people living with HIV: viro-immunological correlations 51
HBs isoforms as innovative biomarkers in predicting virological response in chronic hepatitis delta patients treated with bulevirtide monotherapy. 49
Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo (s) tide analogue (NA) treatment discontinuation in non-cirrhotic patients with Chronic Hepatitis B 48
Kinetics of the three HBsAg forms along with HDV-RNA predict virological and biochemical responses in chronic hepatitis delta patients treated with bulevirtide for 48 weeks. 48
The composition of HBsAg along with HDV-RNA predicts virological response in chronic hepatitis delta patients treated with bulevirtide for 48 weeks. 45
Transcriptionally active HBV integrations frequently occur in the early phases of chronic infection and mostly involve genetic regions crucial for cell proliferation. 45
Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure 44
Biological and clinical significance of classic and innovative virological parameters in the pathogenesis and in the clinical management of HBV infection 44
HBs isoforms can play a role in predicting virological response in patients with chronic hepatitis delta under bulevirtide monotherapy. 43
Intrahepatic HDV Activity Is Fueled By Integrated HBV DNA-Derived HBs Independently From CccDNA Size 38
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study 33
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA 29
Chronic HDV coinfection is characterized by a more elevated production of all three HBsAg isoforms compared to HBV mono-infection, that parallels HDV replicative and cytolytic activity. 29
The burden of HDV chronic infection and the gaps in HDV screening across Europe: an urgent need to strengthen diagnostic strategies at pan-European level 25
Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide 23
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 21
HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential. 21
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 20
Kinetics of occult hepatitis B infection in people with HIV switching from HBV-active ART to long-acting cabotegravir/rilpivirine 18
Malagnino Valutazione della risposta biochimica e virologica dopo 72 settimane di terapia con Bulevirtide ed analisi della cinetica virale intraepatica in una coorte di pazienti affetti da epatite delta. 18
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 17
Totale 8.879
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 0 0 10
2021/2022252 14 7 0 16 9 26 25 17 86 8 1 43
2022/2023485 31 61 44 50 53 76 33 47 38 3 35 14
2023/2024726 138 16 74 49 73 80 38 11 25 134 24 64
2024/20251.952 70 358 227 143 88 159 212 103 200 127 133 132
2025/20264.432 456 171 400 433 439 177 506 533 530 384 247 156
Totale 8.968